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Abstract
Introduction: Recent genome-wide and candidate gene association studies in large numbers of systemic lupus
erythematosus (SLE) patients have suggested approximately 30 susceptibility genes. These genes are involved in
three types of biological processes, including immune complex processing, toll-like receptor function and type I
interferon production, and immune signal transduction in lymphocytes, and they may contribute to the
pathogenesis of SLE. To better understand the genetic risk factors of SLE, we investigated the associations of seven
SLE susceptibility genes in a Chinese population, including FCGR3A, FCGR2A, TNFAIP3, TLR9, TREX1, ETS1 and TNIP1.
Methods: A total of 20 SNPs spanning the seven SLE susceptibility genes were genotyped in a sample of 564
unrelated SLE patients and 504 unrelated healthy controls recruited from Yunnan, southwestern China. The
associations of SNPs with SLE were assessed by statistical analysis.
Results: Five SNPs in two genes (TNFAIP3 and ETS1) were significantly associated with SLE (corrected P values
ranging from 0.03 to 5.5 × 10
-7). Through stratified analysis, TNFAIP3 and ETS1 showed significant associations with
multiple SLE subphenotypes (such as malar rash, arthritis, hematologic disorder and antinuclear antibody) while
TNIP1 just showed relatively weak association with onset age. The associations of the SNPs in the other four genes
were not replicated.
Conclusions: The replication analysis indicates that TNFAIP3, ETS1 and TNIP1 are probably common susceptibility
genes for SLE in Chinese populations, and they may contribute to the pathogenesis of multiple SLE
subphenotypes.
Introduction
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease with marked clinical heterogeneity. The
integral components of SLE pathology - including
abnormal function of B cells and T cells that generates
autoreactive lymphocytes and responses to many self-
antigens, the perpetual production of a broad variety of
autoantibodies that cause incomplete clearance and sub-
sequent tissue deposition of immune complexes, the
activation of complement and defective cellular apopto-
sis that generate a pool of potential autoantigens, and
the expression of proinflammatory cytokines - all result
in intense inflammation and multiple organ damage
Patients can be diagnosed as having SLE when they
meet any four of 11 American College of Rheumatology
classification criteria [1,2]. Genetic factors have been
demonstrated to contribute to the susceptibility of SLE
because of familial clustering [3-5] and increased con-
cordance in monozygotic twins [6,7]. Since the 1970s,
genetic analyses have been conducted to seek the sus-
ceptibility genes in SLE patients [8]. Especially, in the
past 5 years, genome-wide association (GWA) and case-
control studies in a large number of SLE patients have
significantly expanded our understanding of the genetic
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identified as playing important roles in SLE pathogen-
esis, and most of these genes have been shown to act in
three types of biological processes: immune complex
processing, toll-like receptor (TLR) function and type I
interferon production, and immune signal transduction
in lymphocytes [8,18,21,22]. These findings have
revealed many robust associations and the related biolo-
gical pathways involved in this complex disease. As an
unusually heterogeneous disease, however, the genetic
risk factors of SLE are yet to be fully dissected by con-
ducting more studies, especially replications in popula-
tions with different ethnic backgrounds.
Among the top candidates for SLE susceptibility
genes, Fcg receptors (FCGRs) are involved in immune
complex processing and are associated with SLE patho-
genesis. Particularly, FCGR2A and FCGR3A possess
functional variants, including missense mutations
(FCGR2A H131R and FCGR3A V176F) that decrease
their binding affinity to human IgG and affect the clear-
ance of immune complexes [8,18,21,23-25]. Two mis-
sense mutations have been suggested to confer the
increased risk for SLE [18,24,25] in spite of inconsistent
results in different populations [26,27]
Type I interferon has been implicated in SLE patho-
physiology, and there have been several genes identified
in the related pathway [21]. The overproduction of type
I interferon can promote the maturation of dendritic
cells, and the expression of proinflammatory cytokines
and chemokines, leading to diverse effects on immune
functions including the activation of autoreactive B cells
and T cells, the production of autoantibodies, and loss
of self-tolerance [28,29].
TNFa-induced protein 3 (TNFAIP3), also known as
the zinc-finger A20 protein, is a ubiquitin-editing
enzyme that restricts both TNF receptor and TLR-
induced NF-B signals, and therefore is required for
effective termination of NF-B-mediated proinflamma-
tory responses [30-32]. In recent GWA studies, genetic
variants in the TNFAIP3 gene have been identified as
contributing to the genetic risk of SLE in both European
and Asian populations [12,15,19]. These variants include
a potential causal SNP (rs2230926), which was suggested
to reduce the ability of A20 to attenuate NF-B signal-
ing, resulting in a high level of type I interferon produc-
tion [15,33].
An important category of innate immune receptors,
TLRs can discriminate self-derived DNA from microbe-
derived DNA. However, they can also be activated by
host-derived nucleic acid; for example, nucleic acid-con-
taining autoantibody complexes or apoptotic or necrotic
cell debris, the deposition of which is a predominant
feature of SLE disease [34,35]. Of the TLRs, TLR9 was
suggested to be involved in the pathogenesis of SLE
because its aberrant activation may lead to the produc-
tion of type I interferon [28].
Another gene related to theD N A - r e c o g n i t i o n - a c t i -
vated type I interferon response pathway is the 3’ repair
exonuclease 1 (TREX1). Normally, TREX1 prevents acti-
vation of cell-intrinsic type I interferon response by
digesting cytosolic single-stranded DNA [36]. When
TREX1 is mutated, however, it will cause the activation
of type I interferon and subsequent autoimmunity. Pre-
vious studies have shown that mutations in TREX1 were
associated with SLE [37]; however, the association was
inconsistent in different populations [38].
We conducted a case-control association study in 564
cases and 504 controls from Yunnan province of south-
western China. We screened a total of seven candidate
genes, including FCGR3A, FCGR2A, TNFAIP3, TLR9,
TREX1 and the two newly identified susceptibility genes
E26 transformation-specific 1 (ETS1)a n dTNFAIP3
interacting protein 1 (TNIP1). The association of ETS1
and TNIP1 with SLE was first reported in a recent Chi-
nese GWA study [19]. TNIP1 interacts with TNFAIP3
and may play a role in NF-B inhibition together with
TNFAIP3. The association of TNIP1 with SLE was also
reported in the GWA study of Europeans [17]. ETS1 is a
member of the E26 transformation-specific family of
transcription factors that control a wide variety of cellular
processes including immune cell differentiation and
development, and was shown to negatively regulate T-
helper type 17 (Th17) cell differentiation and terminal
differentiation of B cells [39,40]. A recent study in Asian
populations demonstrated that reduced expression of
ETS1 may play a role in SLE pathogenesis through
increased differentiation and activity of both plasma cells
and Th17 cells [20]. Although the two new susceptibility
genes were identified through GWA studies in large
number of cases, disease susceptibility has to be validated
via replication study in more populations. The aim of this
replication study is to test the susceptibility of the seven
genes for SLE in a southwestern Chinese population.
Materials and methods
Patients and controls
A total of 564 unrelated SLE patients (89.8% female and
mean age 37.1 ± 13.6) and 504 unrelated healthy con-
trols (87.5% female and mean age 39.3 ± 13.2) were
recruited from 1999 to 2010 in Kunming, Yunnan,
China. All SLE patients fulfilled the American College of
Rheumatology classification criteria [1,2]. We obtained
the detailed clinical data from 450 out of the 564 SLE
patients, which were used for the stratified analysis. The
protocol of the present study was approved by the Insti-
tutional Review Board of Kunming Institute of Zoology,
Chinese Academy of Sciences. Informed consent was
obtained from all participants.
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SNP selection was based on the published data
[15,17-20,23-25,37,41] and the linkage disequilibrium
patterns in the Han Chinese from Beijing plus Japanese
population in the HapMap database (Figure S1 in Addi-
tional file 1). The SNPs rs11581823 and rs7539036 were
selected for FCGR3A; rs10800309, rs4656308 and
rs1801274 for FCGR2A; rs5029924, rs5029936,
rs5029937, rs2230926 and rs610604 for TNFAIP3;
rs187084, rs352140 and rs352162 for TLR9; rs2242150
and rs3135941 for TREX1; rs6590330 and rs4937333 for
ETS1; and rs13168551, rs7708392 and rs10036748 for
TNIP1. A total of 20 SNPs were selected (Table 1).
Genotyping
Venous blood was collected from all participants, and
genomic DNA was extracted using the standard phenol-
chloroform method. DNA samples of the cases and con-
trols were randomly distributed in the DNA plates. All of
the selected SNPs were genotyped by the SNaPShot
method on an ABI 3130 genetic analyzer (Applied Biosys-
tems, Foster City, CA, USA). The SNP genotype callings
were automatically performed using ABI GeneMapper 4.0
(Applied Biosystems, Foster City, CA, USA) and verified
manually. To ensure the accuracy of genotyping, we con-
ducted bidirectional sequencing on 32 randomly selected
individuals; no genotyping errors were found. The geno-
typing success rate for the selected SNPs is 96.7%.
Statistical analysis
Hardy-Weinberg equilibrium and allelic and genotypic
associations were performed in 564 cases and 504 con-
trols using PLINK 1.07 [42]. We also conducted the
association analysis in females only by considering sex
as a covariate. The resulting P values were corrected by
applying the Bonferroni criterion, in which P values
were multiplied by the number of tested SNPs to pro-
duce the Bonferroni-corrected P values. The power to
detect association was calculated using the CaTs pro-
gram [43,44], based on the minor allele frequency of
each SNP in our case-control samples and the effect
size calculated in the allelic association analysis. The
prevalence of 0.06 was used according to the literature
data [45,46].
Table 1 SNP association analysis of the 18 SNPs in all cases and controls
Gene and SNP Position
a Minor allele Minor allele frequency P value Corrected P value
b Odds ratio (95% confidence interval)
Case Control
FCGR3A
rs11581823 1:161517384 C 0.0830 0.0975 0.28 0.84 (0.62 to 1.14)
rs7539036 1:161512731 T 0.0580 0.0714 0.25 0.80 (0.56 to 1.14)
FCGR2A
rs4656308 1:161478751 C 0.1602 0.1456 0.36 1.12 (0.88 to 1.42)
rs1801274 1:161479745 G 0.3565 0.34 0.43 1.08 (0.90 to 1.29)
TNFAIP3
rs5029924 6:138187498 T 0.0817 0.0470 0.0017 0.030 1.80 (1.25 to 2.61)
rs5029937 6:138195151 T 0.0812 0.0448 0.0006 0.012 1.88 (1.30 to 2.73)
rs2230926 6:138196066 G 0.0811 0.0448 0.0007 0.012 1.88 (1.30 to 2.72)
rs610604 6:138199417 G 0.0989 0.0984 1.00 1.00 (0.75 to 1.34)
TLR9
rs187084 3:52261031 C 0.3773 0.3722 0.82 1.02 (0.85 to 1.22)
rs352140 3:52256697 A 0.3686 0.3635 0.82 1.02 (0.86 to 1.22)
rs352162 3:52252969 G 0.3850 0.3770 0.72 1.04 (0.87 to 1.24)
TREX1
rs2242150 3:48505964 A 0.3535 0.3340 0.35 1.09(0.91 to 1.31)
rs3135941 3:48507667 C 0.0326 0.0392 0.47 0.82 (0.52 to 1.32)
ETS1
rs6590330 11:128311059 A 0.4258 0.3086 3.0 × 10
-8 5.5 × 10
-7 1.66 (1.39 to 1.99)
rs4937333 11:128330520 T 0.4814 0.3652 9.3 × 10
-8 1.7 × 10
-6 1.61 (1.35 to 1.92)
TNIP1
rs13168551 5:150462638 T 0.2211 0.2505 0.14 0.85 (0.69 to 1.05)
rs7708392 5:150457485 G 0.2132 0.2587 0.02 0.39 0.78 (0.63 to 0.96)
rs10036748 5:150458146 C 0.2196 0.2552 0.08 0.82 (0.66 to 1.02)
Bold data are significant.
aGenomic positions from NCBI Genome Build 37.1 (GRCh37) [56].
bP values calculated by Fisher’s exact test and then corrected by the
Bonferroni criterion.
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sively confer the genetic risk in one or more specific
subphenotypes and to discover potential association of
certain SNPs with SLE disease, stratified analysis based
on onset age (age 27 was used, according to the litera-
ture data [45-47]) and 11 American College of Rheuma-
tology-defined clinical subphenotypes were conducted,
in which association was assessed by comparing allele
and genotype distributions between patients with a cer-
tain subphenotype and controls, between patients with-
out the subphenotype and controls, and between
patients with and without the subphenotype (paired
patient groups). Often, the associations can be observed
in both of certain paired patient groups. We therefore
compared the frequencies of minor alleles in controls
and paired patient groups (assuming that minor alleles
should be significantly enriched in a certain subpheno-
type if they really contribute to the subphenotype patho-
genesis), and calculated the conditional frequencies of
onset age and other subphenotypes in the paired patient
groups to understand their compositions and to re-eval-
uate certain associations detected in the stratified
analysis.
Results
All SNPs were in Hardy-Weinberg equilibrium in both
cases and controls (P > 0.05 after Bonferroni correction)
except for rs10800309 in controls (P =1 . 6 9×1 0
-9)a n d
rs5029936 in cases (P =8 . 1 7×1 0
-4)-t h e s et w oS N P s
were therefore excluded, resulting in a total of 18 SNPs
for subsequent association analysis. According to the
obtained clinical information, a total of 450 SLE patients
have the complete data for the 11 American College of
Rheumatology clinical subphenotypes, including malar
rash (72.9%), discoid rash (16.2%), photosensitivity
(17.3%), oral ulcers (17.1%), arthritis (75.8%), serositis
(33.8%), renal disorder (60.7%), neurologic disorder
(11.1%), hematologic disorder (82.2%), immunologic dis-
order (75.6%) and antinuclear antibody (97.1%).
Association of TNFAIP3, ETS1 and TNIP1 with SLE
The result of allelic association for each SNP is shown
in Table 1. A total of six SNPs were found to be signifi-
cantly related to SLE (P < 0.05, Table 1), and five of
them remained significant after Bonferroni correction,
including three SNPs in TNFAIP3 (rs5029924,
rs5029937 and rs2230926) and two SNPs in ETS1
(rs6590330 and rs4937333). The SNP rs7708392 in
TNIP1 showed weak association (P = 0.0211, uncor-
rected), but became nonsignificant after correction.
Association analysis using the genotype data generated
similar results (Table S1 in Additional file 1). The
results remained the same when only females were con-
sidered (data not shown).
Lack of association of FCGR3A, FCGR2A, TLR9 and TREX1
with SLE
Significant association with SLE was not observed in the
selected SNPs for FCGR3A, FCGR2A, TLR9 and TREX1
in either the allelic or the genotypic association analyses
(Table 1; see also Table S1 in Additional file 1). The
same results were obtained when only considering the
females (data not shown).
The power calculation was performed (Table S2 in
Additional file 1) to detect false-positive and false-nega-
tive association results. For SNPs rs5029924, rs5029937
and rs2230926 in TNFAIP3, rs6590330 and rs4937333
in ETS1, and rs7708392 in TNIP1, the sample size of
this study showed relatively high power (76 to 100%) to
detect association when allowing a false-positive rate of
0.05; however, the sample size showed rather low power
for the other SNPs (0 to 57%). It is noteworthy that
SNPs rs610604 (in TNFAIP3), rs187084, rs352140 and
rs352162 (in TLR9)s h o w e dar a t h e rl o we f f e c ts i z e
(odds ratio (OR) = 1.00 to 1.04), implying that they have
almost no or a rather weak contribution to SLE patho-
genesis in the Chinese population. As for the SNPs in
FCGR2A and TREX1, although no significant association
was detected (probably due to the small sample size),
the same trend was observed as reported in previous
studies [14,18,37].
Stratified analysis
As shown in Figure 1 (see also Table S3 in Additional
file 1), the SNPs rs5029924, rs5029937 and rs2230926 in
TNFAIP3 were observed to be significantly associated
with onset age and most of the clinical subphenotypes,
including malar rash, arthritis, serositis, neurologic dis-
order, hematologic disorder, immunologic disorder and
antinuclear antibody (OR = 1.67 to 3.18, P =0 . 0 2 1t o
0.001). For ETS1, SNPs rs6590330 and rs4937333
showed significant association with onset age and multi-
ple clinical subphenotypes, including malar rash, photo-
sensitivity, arthritis, serositis, renal disorder, hematologic
disorder, immunologic disorder and antinuclear anti-
body (OR = 1.50 to 1.98, P = 0.003 to 1.9 × 10
-7). For
TNIP1, the SNP rs7708392 was also observed to be
associated with onset age as well as several subpheno-
types, including malar rash, renal disorder, immunologic
disorder and antinuclear antibody (OR = 0.75 to 0.76, P
= 0.017 to 0.043). In addition, the minor allele
(rs3135941C) in TEX1 showed a weak association with
t h es u b p h e n o t y p eo fn e u r o l o g i cd i s o r d e r( w i t haz e r o
frequency in this subphenotype, P = 0.042). The genoty-
pic analysis with the subphenotypes generated similar
results (Table S4 in Additional file 1).
As expected, certain SNPs also showed significance in
both of the paired patient groups (Figure 1; see also
Tables S3 and S4 in Additional file 1). Significance was
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(TNFAIP3) in the paired patient groups of onset age
and subphenotypes of serositis and neurologic disorder;
for rs6590330 and rs4937333 (ETS1)i nt h ep a i r e d
patient groups of onset age and subphenotypes of malar
rash, photosensitivity, arthritis, serositis and renal disor-
der; and for rs7708392 (TNIP1) in the paired patient
groups of antinuclear antibody (Figure 1). Interestingly,
0 1 2 3 4
Age < 27 (84) vs. control (504)
Age <27 (84) vs. age >= 27 (336)
Age >= 27 (336) vs. control (504) Onset age
0 1 2 3 4
P (328) vs. control (504)
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012345
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P (73) vs. control (504)
P (73) vs. N (377)
N (377) vs. control (504) Discoid rash
0123456 0 1 2 3 4
P (78) vs. control (504)
P (78) vs. N (372)
N (372) vs. control (504) Photosensitivity
012345
01234
0 1 2 3 4
P (77) vs. control (504)
P (77) vs. N (373)
N (373) vs. control (504) Oral ulcers
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0123456
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 disorder
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Figure 1 Associations of TNFAIP3, ETS1 and TNIP1 with systemic lupus erythematosus assessed by stratified analysis. P, patient group
with a certain subphenotype; N, patient group without the subphenotype. Number in parentheses is the sample size. Vertical dashed line in
each subphenotype panel indicates the cutoff value of statistical significance (P = 0.05).
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cance in the patient groups without the subphenotypes
of oral ulcers and neurologic disorder when compared
with the patient groups with these subphenotypes.
To discern between true and false associations, we
compared the frequency distribution of the minor allele
(only for TNFAIP3, ETS1 and TNIP1) in controls and
the paired patient groups based on ORs (Figure 1) and
compared the composition of these paired patient
groups by calculating the conditional frequencies of
onset age and other subphenotypes (Figure 2). Risk
alleles of TNFAIP3 and ETS1 were found to be signifi-
cantly enriched in subphenotypes of malar rash, arthri-
tis, hematologic, neurologic and subphenotype
antinuclear antibody - with the highest OR when com-
paring the patient group with the subphenotype with
the controls, and the lowest OR when comparing the
patient group without the subphenotype with the con-
trols. Likewise, protective alleles of TNIP1 were found
to have a similar enrichment pattern when considering
onset age. We believe that these associations are prob-
ably true positive. As for the comparison of the compo-
sition of paired groups shown in Figure 2, most of them
are similar. Although only a few subphenotypes showed
the difference of conditional frequency, they would help
excluding the false positive. For example, TNFAIP3
showed significance and the enrichment of minor allele
in both of the paired groups for onset age, which have
different frequencies in malar rash-positive patients (P <
0.01). Since the malar rash subphenotype was signifi-
cantly related with TNFAIP3, its decreased frequency in
patients aged ≥ 27 reduced the corresponding effect
size, suggesting that the association of TNFAIP3 with
onset age was probably caused by other subphenotypes
associated with TNFAIP3. Another example is that ETS1
showed significance and a larger effect size in patient
groups without discoid rash, which was probably due to
the significantly increased frequency of antinuclear anti-
body (Figure 2).
Discussion
Among the seven genes tested for SLE susceptibility,
three (TNFAIP3, TNIP1 and ETS1) were successfully
replicated for the associations. Consistent with recent
studies [19,20,48-50], rs2230926 in TNFAIP3, rs7708392
in TNIP1, and rs4937333 and rs6590330 in ETS1
showed significant associations with SLE (Table 1; see
also Table S1 in Additional file 1). The SNP rs2230926
in TNFAIP3 is a nonsynonymous variant, and the risk
allele (rs2230926G) was suggested to downregulate the
expression and activity of inhibiting the TNF-induced
NF-B activity of A20 protein [15]. A recent study
demonstrated that the functional variant TT > A was
significantly associated with SLE in European and Kor-
ean populations, leading to reduced TNFAIP3 mRNA
and A20 protein expression [33]. Similarly, a functional
SNP (rs1128334), tightly linked with rs6590330 and
located in the 3’ UTR of ETS1, was significantly asso-
ciated with lower expression of ETS1 in SLE patients (P
< 0.0001) [20]. Since ETS1 is a negative regulator for
the differentiation of both Th17 cells and B cells, the
decreased expression of ETS1 possibly contributes to
the SLE pathogenesis through the increased differentia-
tion and activity of both plasma cells and Th17 cells
[20,39,40]. Combined with the reported data and the
power calculation (Table S2 in Additional file 1), our
results support TNFAIP3 and ETS1 as probable com-
mon genetic risk factors for SLE in different
Age onset (< 27)
Malar rash (P)
Discoid rash (P)
Photosensitivity (P)
Oral ulcers (P)
Arthritis (P)
Serositis (P)
Renal disorder (P)
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Hematologic disorder (N)
Immunologic disorder (N)
AntiNnuclear antibody (N)
Age onset (< 27)
Malar rash
Discoid rash
Photosensitivity
Oral ulcers
Arthritis
Serositis
Renal disorder
Neurologic disorder
Hematologic disorder
Immunologic disorder
 0   1.0 0.8 - 0.6 0.6 - 0 1.0 - 0.8 p < 0.05 p < 0.01
Anti-nuclear antibody
Figure 2 Comparison of the composition of each patient group
with or without a certain subphenotype. P, patient group with a
certain subphenotype; N, patient group without the subphenotype.
The area of each cycle is proportional to the conditional frequency,
which is the proportion of each subphenotype (upper side of
figure) in a P or N group.
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Page 6 of 9populations, highlighting the importance of two biologi-
cal pathways: type I interferon (involving TNFAIP3)a n d
immune signal transduction in lymphocytes (involving
ETS1).
The observed association for TNIP1 in our samples
was weak. This gene was recently identified in European
(rs7708392) and Chinese (rs10036748) populations via
GWA studies [17,19], and its association with SLE has
been replicated in Japanese (rs7708392) and Han Chi-
nese (rs10036748) populations [48,51]. In our samples,
the G allele of rs7708392 showed a protective effect for
SLE (allele frequency in SLE: 21.3%, control: 25.9%; OR
= 0.78, 95% confidence interval = 0.63 to 0.96, P =
0.02), which is similar to the results reported in a Japa-
nese population [48]. Interestingly, the G allele frequen-
cies of rs7708392 are highly different between Asian
(~30%) and European (~70%) populations, suggesting
genetic heterogeneity at this locus among different
populations. Although the selected SNPs in TNIP1
showed weak associations with SLE, they have a very
similar minor allele frequency distribution to a recent
Chinese GWA study (rs10036748: 20.5% in cases and
25.4% in controls, OR = 0.80) [19]. The power calcula-
tion (76%) suggested the reliability of the association of
TNIP1 with SLE and also indicated that a larger sample
size could help further confirm the role of TNIP1 in
Chinese SLE patients.
We did not replicate the associations of the other four
genes (FCGR3A, FCGR2A, TLR9 and TREX1)i no u r
samples (Table 1; see also Table S1 in Additional file 1).
FCGR3A and FCGR2A are involved in the clearance of
immune complexes, and TLR9 and TREX1 may promote
the production of type I interferon [28,36]. The pre-
viously proposed SLE susceptibility of these four genes
was inconsistent among different populations
[26,27,38,41]. No association was reported in Chinese,
Korean and Japanese populations [26,38,41,52], although
weak associations of several SNPs were observed; for
example, rs396991 in FCGR3A [53], rs1801274 in
FCGR2A [54], rs352140 in TLR9 [55] and the TREX1
polymorphism -20260G > C [38]. Hence, whether these
four genes contribute to SLE susceptibility calls for
more studies, as implied in the power calculation results
(Table S2 in Additional file 1).
In the stratified analysis, TNFAIP3, ETS1 and TNIP1
remained the significant associations with SLE (Figure 1;
see also Tables S3 and S4 in Additional file 1). TNFAIP3
and ETS1 were significantly associated with most sub-
phenotypes, but none of them showed association with
oral ulcers (Figure 1). As for TNIP1, the minor allele of
rs7708392 was associated with a few SLE subphenotypes
including malar rash, renal disorder and antinuclear
antibody, which were also observed in the Japanese
population [48]. It should be noted among several
subphenotypes with high frequencies that malar rash,
hematologic disorder, immunologic disorder and anti-
nuclear antibody co-occurred in 48% of patients, and
the last three subphenotypes showed a higher frequency
of co-occurrence (62.67%). These features may cause
false-positive associations as long as one of these co-
occurred subphenotypes contributes greatly to the
pathogenesis of SLE. We should therefore be cautious in
interpreting the association results of SLE subpheno-
types, and functional data are needed to confirm the
contributions of the risk genes to the SLE pathogenesis.
Conclusions
Our replication study confirmed the association of
TNFAIP3, ETS1 and TNIP1 with SLE susceptibility in a
southwestern Chinese population. In particular,
TNFAIP3 and ETS1 are probably common genetic risk
factors for SLE among Asian populations, and they con-
tribute to most of the clinical subphenotypes of SLE,
supporting the critical roles of two recently proposed
biological pathways: type I interferon and immune signal
transduction in lymphocytes in the pathogenesis of SLE.
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Figure S1 shows gene structures and linkage disequilibrium plots
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